Minoxidil is a drug that widens small arteries. It was first approved in the US in 1979 as an oral tablet (Loniten) for severe high blood pressure. Excess hair growth turned out to be its most common side effect, and a topical scalp version (Rogaine) followed in 1988. Today topical minoxidil is sold over the counter for pattern hair loss, and oral minoxidil remains a prescription blood pressure drug.
Pattern hair loss (androgenetic alopecia) affects up to 80% of white men and 42% of women (Kanti et al., JEADV 2018). As the name says, it depends on androgens, so it is a common concern for people exposed to testosterone and other anabolic steroids. Minoxidil does not touch the hormonal side of the problem. It does not block androgens or their conversion to DHT, so it works differently from finasteride and dutasteride. The single most important fact is that the hair-loss use is approved only for the topical product. Taking the tablets at low doses for hair is an off-label practice.
This page summarizes what the FDA-approved labels, randomized trials and safety studies report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Drug class | Direct-acting peripheral vasodilator; potassium-channel opener (via its sulfate metabolite) |
| Brands / approval | Loniten tablets (NDA 018154, approved 1979, brand now discontinued; generics available); Rogaine topical (NDA 019501, approved 1988) |
| Routes | Oral tablet (prescription); topical solution or foam (over the counter) |
| Strengths | Tablets 2.5 mg and 10 mg; topical 2% and 5% |
| Approved uses | Oral: severe hypertension resistant to three other drugs. Topical: pattern hair loss in adults |
| Half-life (oral label) | 4.2 h in plasma; the blood pressure effect lasts about 75 h |
| Boxed warning (oral) | Pericardial effusion and tamponade, worsening angina; must usually be given with a diuretic and a beta-blocker |
| Most common side effect | Excess body and facial hair (hypertrichosis): about 80% of patients on oral blood pressure doses |
| US status | Not a controlled substance |
| WADA status | Not on the 2026 Prohibited List |
What it is
Minoxidil is a small pyrimidine compound, chemically 2,4-pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide. Its formula is C₉H₁₅N₅O and its molecular weight is 209.25 g/mol (oral minoxidil label). It is not a hormone and is not related to the steroids.
The drug itself is largely a precursor. Sulfotransferase enzymes convert it to minoxidil sulfate, which opens ATP-sensitive potassium (KATP) channels in the smooth muscle of artery walls. The muscle relaxes and the arteries widen, which lowers blood pressure (Messenger & Rundegren, Br J Dermatol 2004).
How it makes hair grow is less clear:
- The sulfate is the active form at the follicle. In cultured mouse whisker follicles, minoxidil sulfate was 14 times more potent than minoxidil, and drugs that blocked sulfation also blocked the hair effect (Buhl et al., J Invest Dermatol 1990).
- It acts on the hair cycle. In animal studies, topical minoxidil shortens the resting phase (telogen) and pushes follicles into the growth phase (anagen) early. It may also lengthen anagen and enlarge follicles. The review authors consider a similar action probable in humans.
- The potassium-channel link is unproven in hair. No clear demonstration that KATP channels are expressed in the hair follicle existed when the main mechanistic review was written (Messenger & Rundegren 2004).
The oral label notes that no hormonal abnormality explains the extra hair growth. It describes it as “hypertrichosis without virilism.”
Forms
| Form | Status in the US | Labeled use | Labeled directions |
|---|---|---|---|
| Oral tablets, 2.5 mg and 10 mg | Prescription | Severe, resistant hypertension | Start 5 mg/day; usual 10–40 mg/day; maximum 100 mg/day |
| 2% topical solution | Over the counter (men’s and women’s versions) | Hair regrowth on the scalp | 1 mL twice daily |
| 5% topical solution (men) | Over the counter | Vertex hair regrowth in men | 1 mL twice daily |
| 5% foam (men) | Over the counter | Vertex hair regrowth in men | Half a capful twice daily |
| 5% foam (women) | Over the counter | Hair regrowth on the top of the scalp in women | Half a capful once daily |
Sources: oral label; Rogaine Drug Facts labels for men’s foam, men’s 5% solution, women’s foam and women’s 2% solution.
No oral product is approved for hair loss in the US. The tablet label states that using minoxidil tablets “in any formulation” to promote hair growth is not an approved indication.
Pharmacokinetics
The figures below are for the oral tablet (oral minoxidil label):
| Parameter | Value |
|---|---|
| Absorption from the gut | At least 90% |
| Time to peak plasma level | Within the first hour |
| Plasma half-life | 4.2 h on average |
| Metabolism | About 90% metabolized, mainly by glucuronidation |
| Protein binding | None |
| Brain penetration | Does not cross the blood-brain barrier |
| Excretion | Mainly in urine; removable by hemodialysis |
| Onset of blood pressure drop | Within 30 minutes; lowest at 2–3 h |
| Duration of blood pressure effect | About 75 h after one effective dose |
The short plasma half-life is misleading on its own. The blood pressure effect does not track plasma levels and fades at about 30% per day. Despite the 4-hour half-life, the label allows once-daily dosing when diastolic pressure has been lowered by less than 30 mmHg.
The label also warns that topical minoxidil can be absorbed into the body, and that the amount depends on the vehicle and how it is used. For that reason it says home-made or compounded topical preparations should be treated as carrying the full set of oral warnings.
Approved medical use
Severe hypertension (oral)
The tablet label restricts oral minoxidil to hypertension that causes symptoms or organ damage and is not controlled by maximum doses of a diuretic plus two other blood pressure drugs. Milder hypertension is not an approved use. In the trials behind the label, minoxidil lowered supine diastolic pressure by 20 mmHg, or to 90 mmHg or lower, in about 75% of patients, most of whom had failed other drugs.
Because widening the arteries makes the body hold salt and water and speeds up the heart, the label says it must usually be given with:
- a diuretic, almost always a loop diuretic, to prevent fluid overload and heart failure;
- a beta-blocker or another drug that suppresses the sympathetic nervous system, to prevent a fast heart rate and angina.
Pattern hair loss (topical)
The FDA approval history on Drugs@FDA shows these milestones (Drugs@FDA):
| Date | Event |
|---|---|
| October 18, 1979 | Loniten tablets approved as a new molecular entity |
| August 17, 1988 | Rogaine 2% topical solution approved |
| February 9, 1996 | Rogaine switched from prescription to over the counter |
| November 14, 1997 | 5% solution for men approved |
| January 20, 2006 | 5% foam approved |
The labels limit use to adults aged 18 and over with gradual, hereditary hair loss on the top of the scalp. The men’s 5% products state that they are not intended for frontal baldness or a receding hairline. The labels advise against use when hair loss is sudden, patchy, of unknown cause, or (for women) linked to childbirth.
The labels also set expectations about timing and duration:
- Men: results may appear at 2 months of twice-daily use, but some men need at least 4 months.
- Women: with the once-daily 5% foam, results may appear at 3 months, but some women need at least 6 months.
- Continued use is required. If treatment stops, hair loss resumes.
- More is not better. All labels state that using more, or more often, will not improve results.
What the research shows
Topical minoxidil in men
The pivotal trial randomized 393 men aged 18–49 to twice-daily 5% solution, 2% solution or placebo for 48 weeks (Olsen et al., JAAD 2002). The 5% solution beat both 2% and placebo on hair counts, patient ratings and investigator ratings. At week 48 it produced 45% more hair regrowth than the 2% solution, and the response appeared earlier. Itching and local irritation were more common with 5%.
A later 16-week trial in 352 men tested the 5% foam, which contains no propylene glycol, against placebo (Olsen et al., JAAD 2007). Hair counts rose significantly more with the foam (p under 0.0001), and 143 men continued in an open-label safety phase to 52 weeks. Efficacy was not measured beyond 16 weeks.
The current men’s 5% solution label adds that hair regrowth “has not been shown to last longer than 48 weeks” in large clinical trials of continuous treatment.
Topical minoxidil in women
| Trial | Design and n | Arms | Main result |
|---|---|---|---|
| Lucky et al., JAAD 2004 | Randomized, 48 weeks, 381 women aged 18–49 | 5% solution twice daily, 2% solution twice daily, placebo | 5% beat placebo on all 3 primary outcomes; 2% beat placebo on hair count and investigator rating; 5% beat 2% only on patients’ rating of benefit |
| Bergfeld et al., J Drugs Dermatol 2016 | Randomized phase III, 24 weeks, 404 women | 5% foam once daily vs vehicle foam | +10.9 hairs/cm² at week 12 and +9.1 hairs/cm² at week 24 vs vehicle (both p under 0.0001) |
The women’s 2% solution label reports that after 8 months, 19% of women had moderate regrowth and 40% minimal regrowth, compared with 7% and 33% on placebo (Women’s Rogaine 2% label). In the Lucky trial, the 5% solution caused more itching, irritation and hypertrichosis than 2%.
A 2016 Cochrane review of female pattern hair loss included 47 trials with 5,290 participants, 17 of which tested minoxidil (van Zuuren et al., Cochrane 2016):
| Outcome (minoxidil vs placebo) | Result (95% CI) | Evidence quality |
|---|---|---|
| Patient-rated moderate to marked regrowth | 157/593 vs 77/555; RR 1.93 (1.51–2.47) | Moderate |
| Investigator-rated regrowth (7 studies, 1,181 people) | RR 2.35 (1.68–3.28) | Moderate |
| Total hair count (8 studies, 1,242 people) | +13.18 hairs/cm² (10.92–15.44) | Low |
| Adverse events, 2% twice daily | RR 1.24 (0.82–1.87) | Low |
| 2% vs 5%, total hair count (3 studies, 631 people) | MD −2.12 hairs/cm² (−5.47 to 1.23); no difference | Low |
In other words, the Cochrane authors found good support for topical minoxidil in women but no clear advantage of 5% over 2%.
Low-dose oral minoxidil for hair loss
Oral minoxidil at doses well below those used for hypertension is now widely prescribed off-label for hair loss. The controlled evidence is still limited.
Head-to-head trial in men. A double-blind trial at one Brazilian clinic randomized 90 men aged 18–55 to oral minoxidil 5 mg daily plus a placebo solution, or 5% topical minoxidil twice daily plus a placebo tablet, for 24 weeks; 68 completed (Penha et al., JAMA Dermatol 2024):
| Outcome at week 24 | Difference, oral minus topical (95% CI) | p |
|---|---|---|
| Terminal hair density, frontal | +3.1 hairs/cm² (−18.2 to 21.5) | 0.27 |
| Terminal hair density, vertex | +23.4 hairs/cm² (−0.3 to 43.0) | 0.09 |
| Photographic assessment, vertex | +24% (0 to 48) | 0.04 |
| Photographic assessment, frontal | +12% (−12 to 36) | 0.24 |
Oral minoxidil was not superior on the primary outcome. In the oral group, 49% (22 of 45) developed hypertrichosis and 14% (6 of 45) had headaches.
Pooled trials. A 2025 meta-analysis of 4 randomized trials (279 patients, 24–39 weeks) found no difference between oral and topical minoxidil in hair density (SMD 0.02, 95% CI −0.25 to 0.29). Excess hair growth was twice as common with oral dosing (RR 2.01, 95% CI 1.18–3.41) (Sobral et al., Int J Dermatol 2025).
Indirect comparisons. A network meta-analysis of 23 studies in men compared treatments across trials rather than head to head (Gupta et al., JAMA Dermatol 2022):
- At 24 weeks, oral minoxidil 5 mg/day ranked highest for terminal hair count. It exceeded topical 5% by 29.8 hairs/cm² (95% CI 19.7–39.8) and finasteride 1 mg/day by 10.4 hairs/cm² (2.2–18.6).
- At 48 weeks, finasteride 1 mg/day ranked highest for terminal hair count, exceeding topical 5% minoxidil by 26.2 hairs/cm² (16.2–36.2).
Indirect estimates like these are weaker than direct randomized comparisons. The one direct trial above did not confirm a clear advantage of oral over topical minoxidil.
Side effects and risks
Boxed warning (oral tablets)
The tablet label carries a boxed warning. It states that minoxidil “may produce serious adverse effects,” including:
- pericardial effusion (fluid around the heart), occasionally progressing to tamponade, in which the fluid compresses the heart;
- worsening angina, from the faster heart rate and higher cardiac output.
The label reports pericardial effusion in about 3% of treated patients not on dialysis, especially those with poor kidney function. These figures come from patients with severe hypertension, for whom the label’s usual effective dose is 10–40 mg/day.
Other risks at blood pressure doses
| Effect | Rate on oral label |
|---|---|
| Hypertrichosis (longer, thicker, darker fine hair on face and body) | About 80%, starting within 3–6 weeks; takes 1–6 months to reverse after stopping |
| ECG T-wave changes, without symptoms | About 60% |
| Temporary edema in patients without prior edema | 7% |
| Drop in hematocrit and hemoglobin from fluid expansion | About 7% initially, then recovery |
| Rash | Under 1%; rare Stevens-Johnson syndrome and toxic epidermal necrolysis |
| Breast tenderness | Under 1% |
The label lists one contraindication besides hypersensitivity: pheochromocytoma, a tumor that releases adrenaline-like hormones, because minoxidil may trigger their release. It also warns of a serious interaction with guanethidine, an older blood pressure drug, which can cause profound drops in blood pressure on standing.
In animal studies, minoxidil caused heart lesions in dogs and minipigs, including scarring of the heart muscle and bleeding in the atria. The label notes that these lesions were not found in a review of over 150 autopsies of treated patients.
Safety of low-dose oral minoxidil
The data for off-label low doses come mainly from retrospective case series and small studies without control groups:
- The largest series reviewed 1,404 patients (67% women; mean age 43) treated for at least 3 months (Vañó-Galván et al., JAAD 2021). Excess hair growth occurred in 15.1%. Systemic effects were lightheadedness (1.7%), fluid retention (1.3%), fast heart rate (0.9%), headache (0.4%), swelling around the eyes (0.3%) and insomnia (0.2%). In total, 1.7% stopped because of side effects, and no life-threatening events were seen.
- Blood pressure. A meta-analysis of studies using up to 5 mg/day found no significant change in systolic (−0.13 mmHg, 95% CI −2.67 to 2.41) or diastolic pressure (−1.25 mmHg, −3.21 to 0.71). Heart rate rose by 2.67 beats per minute (0.34–5.01), and 5.0% of patients reported symptoms of low blood pressure (Chen et al., JAAD 2025).
- Pericardial effusion. In a cross-sectional ultrasound study of 100 alopecia patients, small effusions (under 1 cm) were found in 5.8% of those on low-dose oral minoxidil and 6% of controls, none with symptoms (Kincaid et al., J Drugs Dermatol 2024). However, an analysis of the FDA adverse event reporting database found a reporting signal for pericardial effusion at every dose range studied, including 1.25 mg or less (Gupta et al., J Cosmet Dermatol 2025). Such signals show disproportionate reporting, not proof of cause.
Topical side effects
The main problems with topical minoxidil are local:
- Itching and irritation, more common with 5% than with 2% solution in both the men’s and women’s trials.
- Allergic contact dermatitis. A review of 99 patch-test-confirmed cases found minoxidil itself was the main allergen in 74.7%, and propylene glycol (a solvent in many solutions, absent from the foam) in 17.1% (Kiratiwongwan et al., Dermatitis 2025).
- Hypertrichosis, more common with 5% than 2% solution in women.
- Changes in hair color or texture, listed on the product labels.
The labels tell users to stop and see a doctor for chest pain, a racing heart, faintness, dizziness, sudden weight gain, or swollen hands or feet, which can signal systemic absorption.
Pregnancy, breastfeeding and children
The topical labels state that minoxidil may be harmful during pregnancy or breastfeeding, and must not be used on babies or children. The oral label reports newborn hypertrichosis after exposure during pregnancy, and advises against use while nursing because minoxidil has been found in breast milk.
Children can also be exposed indirectly. Case reports describe severe excess hair growth in infants whose parents used 5% or 7% topical minoxidil, with transfer through skin contact or shared objects (Rica Echevarría et al., Dermatol Ther 2020).
Who should be cautious
Based on the labels:
- Heart disease. The topical labels say to ask a doctor first; the oral label warns of angina, fluid retention and pericardial effusion.
- Kidney failure or dialysis. The oral label notes higher risk of fluid problems and effusion, and that smaller doses may be needed.
- Recent heart attack. Oral minoxidil has not been studied within a month of a heart attack.
- Pheochromocytoma. Contraindicated for the oral drug.
Legal status
Topical minoxidil 2% and 5% is sold over the counter in the US. Oral minoxidil requires a prescription, and its only approved use is severe hypertension. Minoxidil is not a controlled substance and is not listed on the WADA 2026 Prohibited List.
Key takeaways
- A blood pressure drug that grows hair. Minoxidil widens arteries through its sulfate metabolite. The hair effect is real but its mechanism is not fully understood.
- It does not act on hormones. It does not block androgens or DHT, so it works through a different route than finasteride or dutasteride.
- Topical is the approved hair-loss form. In men, 5% beat 2% and placebo over 48 weeks. In women, Cochrane found clear benefit but no proven edge of 5% over 2%. Gains last only while treatment continues.
- Low-dose oral use is off-label. The one head-to-head trial in men found 5 mg/day oral was not superior to 5% topical. Excess body and facial hair was common, affecting 49% in that trial.
- The oral drug has serious warnings at full doses. Pericardial effusion, fluid retention and angina are labeled risks. At low doses, large case series report few systemic effects, but controlled long-term safety data are lacking.
Sources
- Par Health USA. Minoxidil tablets, USP, prescribing information (revised 05/2026). DailyMed.
- Kenvue Brands. Men’s Rogaine 5% minoxidil foam; Men’s Rogaine Extra Strength 5% solution; Women’s Rogaine 5% foam; Women’s Rogaine 2% solution. Drug Facts labels. DailyMed: men’s foam, men’s 5% solution, women’s foam, women’s 2% solution.
- US Food and Drug Administration. Drugs@FDA: NDA 018154 (Loniten), NDA 019501 (Rogaine), NDA 020834 (Rogaine Extra Strength), NDA 021812 (Rogaine foam). Drugs@FDA.
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–194. PubMed.
- Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553–557. PubMed.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22. PubMed.
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385. PubMed.
- Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767–774. PubMed.
- Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–553. PubMed.
- Bergfeld W, Washenik K, Callender V, et al. A Phase III, multicenter, parallel-design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss. J Drugs Dermatol. 2016;15(7):874–881. PubMed.
- van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;(5):CD007628. PubMed.
- Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600–605. PubMed.
- Sobral MVS, Moreira JLML, Rodrigues LK, et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol. 2025;64(3):479–484. PubMed.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022;158(3):266–274. PubMed.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644–1651. PubMed.
- Chen M, Weichert M, Guo W, et al. Low-dose oral minoxidil does not significantly affect blood pressure: a systematic review and meta-analysis. J Am Acad Dermatol. 2025;92(3):554–555. PubMed.
- Kincaid CM, Sharma AN, Sargent B, et al. Evaluation of pericardial effusions in alopecia patients on low-dose oral minoxidil therapy. J Drugs Dermatol. 2024;23(9):725–728. PubMed.
- Gupta AK, Bamimore MA, Abdel-Qadir H, et al. Low-dose oral minoxidil and associated adverse events: analyses of the FDA Adverse Event Reporting System (FAERS) with a focus on pericardial effusions. J Cosmet Dermatol. 2025;24(1):e16574. PubMed.
- Kiratiwongwan R, Boonchai W, Kanokrungsee S. Allergic contact dermatitis to topical preparations containing minoxidil: a systematic review and individual participant data meta-analysis. Dermatitis. 2025;36(3):200–206. PubMed.
- Rica Echevarría I, García Del Monte J, Delgado Rubio A, et al. Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil. Dermatol Ther. 2020;33(6):e14230. PubMed.
- World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List.